RxDoctor Payments DataLook up a doctor →

Keith Harris, DO

Pulmonary Disease · Port Jefferson Station, NYNPI 1114026853

Payments from drug & device makers

$853,592in general payments, 2019–2025

Across 1,477 payments — averaging $577.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$434K
  • GSK$195K
  • Grifols USA, LLC$105K
  • Verona Pharma, Inc.$103K
  • Boehringer Ingelheim$10K
  • Hill-rom Company, Inc$875
  • plus $6K from 35 others

What the payments were for

  • Consulting fees$17,2132%
  • Speaking & faculty fees$704,39985%
  • Travel & lodging$73,1849%
  • Food & beverage$36,8684%
  • Education$2280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$853,592 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$690,269
Medicare patients
1,322
Services billed
8,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter427$493,469
OfevNintedanib Esylate19$380,164
ZemairaAlpha-1-Proteinase Inhibitor13$153,230
Breo ElliptaFluticasone/Vilanterol208$129,824
Breztri AerosphereBudesonide/Glycopyr/Formoterol95$107,091
Spiriva RespimatTiotropium Bromide102$99,354
Dupixent PenDupilumab20$71,722
Arnuity ElliptaFluticasone Furoate84$32,557
Stiolto RespimatTiotropium Br/Olodaterol Hcl39$25,123
SymbicortBudesonide/Formoterol Fumarate52$16,064
Spiriva HandihalerTiotropium Bromide19$16,028
Incruse ElliptaUmeclidinium Bromide16$15,200
Albuterol Sulfate HfaAlbuterol Sulfate342$13,613
Combivent RespimatIpratropium/Albuterol Sulfate13$12,586
Advair HfaFluticasone Propion/Salmeterol18$12,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$195,177$671,050735 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$9,837$517,227173 claims
CSL BehringZemaira$27$153,23013 claims
AstraZenecaBreztri Aerosphere, Symbicort$433,521$123,155147 claims
MerckDulera$116$11,49915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →